<DOC>
	<DOCNO>NCT01227317</DOCNO>
	<brief_summary>The purpose study evaluate capacity novel biomarkers Procalcitonin ( PCT ) , Midregional Proadrenomedullin ( MR pro ADM ) , Midregional pro-atrial natriuretic peptide ( MR pro ANP ) , Copeptin ( CT pro arginine vasopressin ) , Pro endothelin stratify risk severe dyspnea .</brief_summary>
	<brief_title>BIOmarkers Dyspnea IN Emergency Room</brief_title>
	<detailed_description>In emergency department shortness breath ( SOB ) common symptom cause easy identify . The risk stratifying remain challenge , Prognostic value biomarkers might helpful .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Emergencies</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Dyspnea</mesh_term>
	<criteria>tachypnea &gt; 25 /min Pa02 &lt; 70 mmHg SpO2 &lt; 93 % diagnosis suspect : CAP , PE , EACOPD , AHF cause dyspnea , unreachable Day 30</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Dyspnea</keyword>
	<keyword>Mortality</keyword>
</DOC>